Antibody‑drug conjugates in prostate cancer: Emerging strategies to enhance therapeutic index and current clinical landscape (Review)
Oncology Reports · 13.12.2024 · 53 (2)
DOI: 10.3892/or.2024.8854 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Oncology Reports, online erschienen am 13.12.2024. Verfasst von Chadanfeng Yang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The Second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650032, P.R. China. Hauptthemen laut MEDLINE: Immunoconjugates, Prostatic Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 107 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, The Second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650032, P.R. China.
Zitieren
APA
Yang, C., Wang, L., Gong, C., Lv, D., Li, H., Huang, Y., Li, J., Chen, W., Fu, S., Tan, Z., & Ding, M. (2024). Antibody‑drug conjugates in prostate cancer: Emerging strategies to enhance therapeutic index and current clinical landscape (Review). Oncology Reports, 53(2). https://doi.org/10.3892/or.2024.8854
Vancouver
Yang C, Wang L, Gong C, Lv D, Li H, Huang Y, et al. Antibody‑drug conjugates in prostate cancer: Emerging strategies to enhance therapeutic index and current clinical landscape (Review). Oncology Reports. 2024;53(2). doi:10.3892/or.2024.8854
BibTeX
@article{Yang2024,
author = {Yang, Chadanfeng and Wang, Limei and Gong, Chen and Lv, Dihao and Li, Haihao and Huang, Yinglong and Li, Jiting and Chen, Wujie and Fu, Shi and Tan, Zhiyong and Ding, Mingxia},
title = {Antibody‑drug conjugates in prostate cancer: Emerging strategies to enhance therapeutic index and current clinical landscape (Review)},
journal = {Oncology Reports},
year = {2024},
volume = {53},
number = {2},
doi = {10.3892/or.2024.8854}
}
EUVIMED